← Back to Search

Nasal and Oral Hygiene for COVID-19 (SNOW Trial)

Phase 2 & 3

Recruiting

Led By Rena Kass, MD

Research Sponsored by Milton S. Hershey Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Adults who are ≥18 -65 years of age

Symptomatic or asymptomatic from SARS-CoV-2

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 days

Awards & highlights

SNOW Trial Summary

This trial is testing whether a 4-day combined intervention of nasal washes with 1% baby shampoo solution and oral gargles with Listerine Antiseptic can reduce the SARS-CoV-2 viral load compared to those using nasal and oral washes with normal saline.

Who is the study for?

This trial is for adults aged 18-65 who have tested positive for COVID-19 within the past 5 days, whether they show symptoms or not. They must be able to use an app for study data and speak English. Excluded are those with nasal surgery history, current pregnancy, previous COVID treatments like monoclonal antibodies or molnupiravir, and those unable to tolerate nasal or oral washes.Check my eligibility

What is being tested?

The SNOW Trial is testing if a combination of nasal washes with baby shampoo solution and mouth gargles with Listerine can reduce the viral load in people infected with SARS-CoV-2 more effectively than using saline solutions alone.See study design

What are the potential side effects?

Potential side effects may include discomfort from the nasal and oral wash procedures. There could also be reactions specific to the ingredients in baby shampoo and Listerine such as irritation or allergic responses.

SNOW Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 18 and 65 years old.

Select...

I have or have not had symptoms from COVID-19.

SNOW Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Viral Load Change from baseline

Secondary outcome measures

4-day trend in viral load change

Acceptability of the intervention as measured by 7 item questionnaire based an acceptability framework described by Sekhon (2017)

Compliance as measured by percent of expected washes completed

+3 more

SNOW Trial Design

4Treatment groups

Experimental Treatment

Active Control

Placebo Group

Group I: Combination of Baby Shampoo Nasal Wash and Listerine GargleExperimental Treatment1 Intervention

Nasal washes with 1% baby shampoo solution and oropharyngeal gargles with Listerine Antiseptic® solution

Group II: Listerine GargleActive Control1 Intervention

Nasal washes with buffered saline solution and oropharyngeal gargles with Listerine Antiseptic® solution

Group III: Baby Shampoo Nasal WashActive Control1 Intervention

Nasal washes with 1% baby shampoo solution and oropharyngeal gargles with saline solution

Group IV: Saline Wash and GarglesPlacebo Group1 Intervention

Nasal washes with buffered saline solution and oropharyngeal gargles with saline solution

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

AXIOM Real Time MetricsUNKNOWN

3 Previous Clinical Trials

545 Total Patients Enrolled

Analytica Ventures LLCUNKNOWN

Milton S. Hershey Medical CenterLead Sponsor

494 Previous Clinical Trials

2,798,642 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

For what age range is this clinical trial seeking participants?

"According to the published eligibility requirements, patients must be between 18-65 years old to participate in this trial. Out of the 1,134 total clinical trials, this leaves 146 for people under 18 and 988 for those over 65."

Answered by AI

What are the prerequisites for participation in this experiment?

"The requirements for this coronavirus clinical trial are that participants should be infected with sars-cov and between the ages of 18-65. There is a total of 200 slots available for enrolment."

Answered by AI

Could you share the aggregate number of people who have signed up for this research project?

"Yes, as indicated by the most recent update on clinicaltrials.gov, this study is looking for 200 more participants at 2 sites. This trial was originally posted on October 1st, 2021."

Answered by AI

Recent research and studies

The Journal of Infectious DiseasesJournal

Virucidal Efficacy of Different Oral Rinses Against Severe Acute Respiratory Syndrome Coronavirus 2

Meister, Toni Luise, Yannick Brüggemann, Daniel Todt, Carina Conzelmann, Janis A Müller, Rüdiger Groß, Jan Münch, et al.. 2020. “Virucidal Efficacy of Different Oral Rinses Against Severe Acute Respiratory Syndrome Coronavirus 2”. The Journal of Infectious Diseases. Oxford University Press (OUP). doi:10.1093/infdis/jiaa471.

Nature MedicineJournal

Sars-cov-2 Entry Factors Are Highly Expressed in Nasal Epithelial Cells Together with Innate Immune Genes

Sungnak, Waradon, HCA Lung Biological Network, Ni Huang, Christophe Bécavin, Marijn Berg, Rachel Queen, Monika Litvinukova, et al.. 2020. “Sars-cov-2 Entry Factors Are Highly Expressed in Nasal Epithelial Cells Together with Innate Immune Genes”. Nature Medicine. Springer Science and Business Media LLC. doi:10.1038/s41591-020-0868-6.

Clinical Infectious DiseasesJournal

Distribution of Transmission Potential During Nonsevere COVID-19 Illness

Shrestha, Nabin K, Francisco Marco Canosa, Amy S Nowacki, Gary W Procop, Sherilynn Vogel, Thomas G Fraser, Serpil C Erzurum, Paul Terpeluk, and Steven M Gordon. 2020. “Distribution of Transmission Potential During Nonsevere COVID-19 Illness”. Clinical Infectious Diseases. Oxford University Press (OUP). doi:10.1093/cid/ciaa886.

The Lancet MicrobeJournal